6,111 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Purchased by NEOS Investment Management LLC

NEOS Investment Management LLC purchased a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,111 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. FMR LLC raised its holdings in shares of Xenon Pharmaceuticals by 2.2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after acquiring an additional 149,511 shares in the last quarter. Walleye Capital LLC purchased a new position in Xenon Pharmaceuticals during the 3rd quarter valued at $4,132,000. Erste Asset Management GmbH bought a new position in Xenon Pharmaceuticals in the 3rd quarter worth $1,932,000. HighVista Strategies LLC lifted its position in shares of Xenon Pharmaceuticals by 1.4% in the 3rd quarter. HighVista Strategies LLC now owns 73,762 shares of the biopharmaceutical company’s stock worth $2,904,000 after purchasing an additional 1,047 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after purchasing an additional 1,507,135 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on XENE shares. StockNews.com raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective for the company. Finally, William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.38.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 22,468 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. The trade was a 41.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Trading Down 2.1 %

NASDAQ XENE opened at $33.55 on Tuesday. Xenon Pharmaceuticals Inc. has a 12 month low of $32.70 and a 12 month high of $46.00. The stock’s fifty day moving average price is $37.62 and its 200-day moving average price is $39.70. The stock has a market cap of $2.57 billion, a P/E ratio of -11.90 and a beta of 1.26.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05. As a group, analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.